AB-FUBINACA was originally developed by Pfizer in 2009 as an analgesic medication,. but was not pursued for human use. Subsequently in 2012, it was discovered as an ingredient in synthetic cannabis blends in Japan. along with a related compound AB-PINACA which had not previously been reported.
Cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. AB-FUBINACA is orally active when dissolved in a lipid, which can increase the duration significantly. Like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.
AB-FUBINACA, or N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide, is a synthetic indazolecarboxamide drug as it contains a substituted indazole core. A 4-substituted fluorophenyl group is bound to this indazole core through a methyl group at R1 of the indazole. This indazole is substituted at R3 with a carboxamide group. The terminal amine of this carboxamide is bonded to a substituted propyl chain with an aminocarbonyl group at R1 and a methyl group at R2.
|Threshold||< 1 mg|
|Light||1 – 2 mg|
|Common||2 – 3 mg|
|Strong||3 – 5 mg|
|Heavy||> 5 mg|
|Total||1 – 2 hours|
|Onset||0 – 20 minutes|
|Peak||30 – 60 minutes|
|Offset||10 – 20 minutes|
|After effects||15 – 30 minutes|
|DISCLAIMER: PW’s dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.|